Sep2024
Passing of Dr. Mohammad Afshar, Founder of Ariana Pharma
It is with profound sadness that we announce the passing of our founder, CEO and Chairman, Dr. Mohammad Afshar, on August 8th, 2024.
Dr. Afshar was a visionary leader, as well as a physician, researcher, entrepreneur, and pioneer in the field of AI and healthcare.
May2024
Ariana is 20… we’ve come a long way
Cast your mind back to when Ariana was founded… Facebook was just launching, Data Scientist had yet to be declared “the sexiest job of the 21st century,” and AI was nowhere near as widespread as today. I vividly recall a potential client asking me, “Why do you do this? This is data torture!” We talked […]
Apr2024
Ariana Pharma announces important Artificial Intelligence (AI) collaboration in precision oncology to accelerate a first-in class antibody blocking lipid metabolism for the treatment of advanced cancer
Artificial Intelligence and organoid data to accelerate the development of a first-in-class antibody in precision oncology. Paris, France and Cambridge, MA, USA, 16th April, 2024, Ariana Pharma, a leading Artificial Intelligence drug development company, announced today that it has entered a €3 million consortium sponsored by the Eurostars 3 program, led by ONA Therapeutics SL, […]
Mar2024
Ariana Pharma Announces Major Artificial Intelligence Collaboration in Cell Therapy with Leading Academic Partners Targeting Immune Regulatory T Cells
Explainable Artificial Intelligence and multi-modal clinical and omic investigations in immunotherapy applied to organ transplantation. Paris, France and Cambridge, MA, USA, March 1st, 2024. Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered a $10 million funded Artificial Intelligence-driven Cell Therapy collaboration with Assistance Publique – Hôpitaux de Paris (AP-HP), […]
May2023
Ariana Pharma continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological […]
Mar2023
Ariana Pharma strengthens SAB with appointment of world-leading Neurologist Jacques Touchon
Cambridge, MA, USA and Paris, France, March 27, 2023 – Ariana Pharma, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.
Nov2022
CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials
• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed
Oct2022
AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX®2-73) in restoring key neurodegenerative pathways
Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France, October 4th, 2022 – Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical […]
Jul2022
Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer
Paris, France and Cambridge, MA, USA, July 26th, 2022 – Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. […]